All rights reserved. No reuse allowed without permission.

Effectiveness of interactive dashboards to optimise prescribing in primary care: A systematic review

 Caroline McCarthy* (0000-0002-2986-5994)¹, Patrick Moynagh (0009-0004-1233-3176)¹, Áine
 Mannion¹, Ashely Wei¹, Barbara Clyne (0000-0002-1186-9495)², Frank Moriarty (0000-0001-9838-3625)³

6

⁷ ¹Department of General Practice, RCSI University of Medicine and Health Sciences, Dublin 2, Ireland

- ² Department of Public Health & Epidemiology, School of Population Health, RCSI University of
 9 Medicine and Health Sciences, Dublin 2, Ireland
- ³ School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences,
 Dublin 2, Ireland
- 12
- 13 ***Corresponding author:** <u>carolinemccarthy@rcsi.com</u>

14 Author roles:

- 15 Caroline McCarthy: Conceptualization, Formal Analysis, Funding Acquisition, Investigation,
- 16 Methodology, Project Administration, Resources, Supervision, Validation, Visualization, Writing –
- 17 Original Draft Preparation, Writing Review & Editing
- 18 Patrick Moynagh: Investigation, Methodology, Project Administration, Resources, Supervision,
- 19 Writing Review & Editing
- 20 Aine Mannion: Investigation, Writing Review & Editing
- 21 Ashley Wei: Investigation, Writing Review & Editing
- 22 Barbara Clyne: Conceptualization, Funding Acquisition, Methodology, Writing Review & Editing
- 23 Frank Moriarty: Conceptualization, Funding Acquisition, Investigation, Methodology, Supervision,
- 24 Validation, Writing Review & Editing

25 **Data Availability:**

- 26 No new primary data were collected for this study, as the review synthesises publicly available data
- 27 from published studies. All data generated or analysed during this study are included in this published

- 28 article and its supplementary information files. This includes the search strategies used for each
- 29 database, details of the included studies, and any additional data extracted during the review process.
- 30 The study protocol is available as an open-access publication and can be accessed directly at
- 31 https://hrbopenresearch.org/articles/7-44.

32 **Competing interests:**

33 The authors have declared that no competing interests exist.

34 Funding:

- 35 CMC is funded by a HRB post-doctoral Clinician Scientist Fellowship award (CSF- 2023-012)
- 36 <u>https://www.hrb.ie/funding/</u>. PM is funded by an ICGP Post CSCST Fellowship award. The funders had
- 37 no role in study design, data collection and analysis, decision to publish, or preparation of the
- 38 manuscript.

39 Abbreviations:

40 PIP, potentially inappropriate prescribing; EHR, electronic healthcare records; RCT, randomised controlled trial; ITSA, interrupted time series analysis; CBA, controlled before and after study; EPOC, 41 42 Effective Practice and Organisation of Care; TIDieR, Template for Intervention Description and 43 Replication; Abx, antibiotic; SABA, short acting beta agonist inhaler; LABA, long acting beta agonist 44 inhaler; NSAID, non-steroidal anti-inflammatory drug; eGFR, estimated glomerular filtration rate; CKD, 45 chronic kidney disease; CVD, cardiovascular disease; CCG, clinical commissioning group; NICE, National 46 Institute for Clinical Excellence; RTI, respiratory tract infection; CDSS, clinical decision support-system; 47 ARR, absolute risk reduction; OR, odds ratio; DDD, defined daily dosage; CI, confidence interval; RP, 48 risky prescribing; AF, atrial fibrillation

49 Word Count (excluding abstract/tables/references): 4020

Abstract	392
Introduction	651
Methods	641
Results	1709
Discussion	1019
	<u>4020</u>

- 51 Tables: 3, Figures: 3
- 52 References: 34

53 Abstract

54 Background

55 Rising levels of both high-risk and low-value prescribing have the potential for adverse effects on 56 patients, healthcare systems and society. It is thus necessary to develop effective and cost-effective 57 interventions to support safe, effective and cost-effective prescribing. Advancements in technology, 58 including machine learning coupled with the vast amounts of routine prescribing data available in 59 primary care have supported the development of novel approaches to provide prescribers with 60 ongoing and comparative prescribing data feedback. This systematic review aimed to explore the 61 characteristics of interactive dashboard interventions in primary care that provide visual and 62 longitudinal feedback on prescription data and to explore the effect of these interventions on 63 prescribing-related outcome measures.

64 Methods and Findings

This systematic review was registered prospectively and reported in line with PRISMA guidelines. 65 66 Multiple databases and grey literature were searched in November 2023 to identify interventional 67 studies, including quasi-experimental designs that explored the effect of interactive dashboards on 68 prescribing-related outcomes in primary care. Identified records were assessed for inclusion and data 69 extraction and risk of bias assessment were completed by two independent researchers. Interventions 70 characteristics and effects were described narratively. A meta-analysis using a random-effects model 71 was performed where at least two studies were comparable in terms of participants, study design and 72 outcomes. Twelve studies, reported across eleven different papers were included, eight randomised 73 controlled trials, one controlled before and after study and three interrupted time series analyses. 74 Nine papers were assessed to be of low risk of bias. Six studies reported a significant effect on 75 prescribing-related outcomes, with an effect seen more often for studies focusing on potentially 76 inappropriate or high-risk prescribing (four out of six studies). Two of the six studies that focused on 77 antibiotic prescribing demonstrated a significant effect. A meta-analysis of three RCTs involving 406

general practices and 337,963 patients demonstrated the overall odds of having at least one potentially inappropriate prescription was 0.87 (95% CI 0.81 to 0.93 $I^2 = 0.0\%$) in the intervention compared to control group.

81 Conclusion

82 Interactive dashboards have the potential to support safe and effective prescribing in primary care.

83 To support their implementation, it is essential to establish the necessary data infrastructure within

84 primary cares systems. This encompasses electronic health records (EHR) systems, data integration

tools, analytics platforms, and compliance with data privacy regulations, all working together to

86 facilitate the efficient use of data for improving prescribing and ultimately patient care.

87

Key Words: Interactive dashboards, potentially inappropriate prescribing, audit and feedback,
 preventable drug related morbidity, polypharmacy, comparative benchmarking, electronic health
 records, routine prescription data.

92 Introduction

93 Prescribing is the most common healthcare intervention and advances in therapeutics have improved 94 the lives and life expectancy of many people living with chronic illness (1). However, alongside these 95 improvements there has been an increase in potentially inappropriate prescribing (PIP) which has 96 potential negative consequences for individuals, society and healthcare systems (2). Prescribing for 97 older patients with multiple chronic illnesses is particularly challenging as prescribers must contend 98 with both potential drug-drug and drug-disease interactions (3). The reasons for potentially 99 inappropriate prescribing are complex and multifaceted and include systems failures, particularly at 100 the interface between primary and secondary care, individual patient factors such as increasing age 101 and multimorbidity, clinician factors such as knowledge and attitudes and broader societal attitudes 102 about the roles and benefits of medicines (4). To both measure and address this, a variety of explicit 103 criteria have been developed for use in both research and clinical practice (5). These measures tend 104 to focus on highly prevalent PIP or those with the potential for significant harm. More recently there 105 has been a shift towards identifying and addressing low-value prescribing, which on a population level 106 can result in harm both directly (e.g. experiencing adverse effects from medicines that are not 107 providing benefit) and indirectly (e.g. contributing to non-adherence and through the opportunity cost 108 of other cost-effective interventions not resourced due to spending on low-value medicines) (6). 109 Explicit measures of medication appropriateness have been demonstrated to be effective at improving 110 prescribing and have the advantage of being relatively reproducible, reliable and easy to apply to large 111 numbers of people (7).

With recent advancements in electronic healthcare records (EHR) and prescribing, it is now possible to apply explicit criteria to routine prescribing or dispensing datasets. OpenPrescribing.net is a prominent example, where the vast amount of anonymous prescription data published by NHS England each month is analysed and presented on a web platform to allow for comparative benchmarking between practices (8). However, when using publicly available anonymous data, only a

117 subset of explicit criteria can be applied as patient-level data such as age and co-morbidities are not 118 included. In addition, it is challenging for clinicians to identify and act on individual instances of sub-119 optimal prescribing. One approach to combine both audit and feedback and clinical decision support 120 (both of which have been identified as effective methods to improve prescribing (9, 10)), while 121 maintaining anonymity, has been to embed code within practice systems and export aggregate-level 122 data (11). This aggregated data can then be fed back to individual practices in the form of interactive 123 dashboards and allow for comparative benchmarking. This approach ensures that individual patient 124 identities are protected while allowing practices to compare their performance, identify areas for 125 improvement and act on individual instances of high-risk prescribing.

126 Identifying appropriate outcome measures is a challenge when assessing the effectiveness of 127 interventions such as interactive dashboards designed to improve prescribing quality in primary care 128 settings. Important clinical endpoints such as unplanned hospital admissions or mortality require a 129 sufficient sample size and an adequate follow-up period to identify any potential effect, which may 130 not be feasible. Thus, composite measures of explicit prescribing criteria are often used as primary 131 endpoints for these studies (12). There is strong observational evidence that such prescribing is 132 associated with adverse outcomes for patients such as increased mortality, falls and unplanned 133 hospital admissions (13). More general prescribing measures include rates of utilisation and these 134 serve as a valuable outcome for evaluating the impact of health policy implementation programmes 135 aimed at modifying prescribing behaviours, such as reducing high opioid prescription levels (14) or 136 imposing restrictions on drugs with unfavourable cost-effectiveness profiles (15).

Given the recent advancements in the data infrastructure of primary care and the need to address both high-risk and low value prescribing, this systematic review aimed to explore characteristics and effectiveness of interactive dashboard interventions on prescribing outcomes in primary care with the additional goal of informing future intervention development and e-prescribing infrastructure.

141

142 Methods

The methods have been described previously in our published protocol (16). This systematic review was prospectively registered on PROSPERO (CRD42023481475), conducted in line with guidance set out in the Cochrane Handbook for Systematic Reviews of Interventions (17), and reported in adherence to PRISMA statement, S1 Appendix (18).

147 Data sources and search strategy

A systematic literature search was conducted 22nd November 2023 in the following databases; 148 149 PubMed, EMBASE, MEDLINE (OVID), PsycINFO (EBSCOhost), CINAHL (EBSCOhost), Scopus and the Cochrane Library (OVID). This was supplemented by grey literature searches in OpenGrey, CADTH Grey 150 151 Matters and the International Clinical Trials Registry Platform (ICTRP) as well as backward and forward 152 citation chasing using an automated citation chaser (19). There were no restrictions placed on 153 language or year of publication. Search terms included keywords to capture the intervention (e.g. 154 "interactive dashboard", "clinical audit", "medical audit", "benchmarking", "data visualisation") the 155 population (e.g. "general practitioner", "primary care*") and the outcomes (e.g. "PIP", "prescribing"). 156 See S2 Appendix for electronic search reports.

157 *Eligibility criteria*

All interventional designs were eligible for inclusion including randomised controlled trials (RCTs) (e.g. 158 159 cluster RCTs, step wedged RCTs and individually randomised RCTs) and non-randomised interventional 160 studies (e.g. interrupted time series design and controlled before and after studies) as recommended by the Cochrane Effective Practice and Organisation of Care (EPOC) group. The population of interest 161 162 was primary care prescribers including non-medical prescribers working in primary care (e.g. 163 pharmacists). An interactive dashboard was defined as a platform designed to provide ongoing 164 feedback of real-time (defined as no older than one year) prescribing data in a visual format and that allowed for comparative benchmarking against peers or a set standard. A true interactive dashboard 165 166 allows direct manipulation of data with visual analytic tools, however studies that did not have an

167 interactive element but provided feedback of multiple parameters and/or configurations from the 168 dataset were also included. Simple clinical decision support interventions or audit and feedback 169 interventions that did not give longitudinal and ongoing feedback of real-time data were both 170 excluded. Multi-faceted interventions that included interactive dashboards alongside other 171 components such as education, clinical decision support or targeted behavioural change strategies 172 were included. The outcome of interest was any prescribing related outcome measure such as explicit 173 prescribing criteria or prescribing rates (e.g. where a higher rate may reflect lower quality such as 174 antibiotic, benzodiazepine or opioid use).

175 *Study selection and data extraction*

176 Identified records were uploaded to Covidence and independently assessed for inclusion based on 177 title and abstract and then full text papers by two researchers (CMC, PM, AM, AW, FM), blinded to 178 each other's decisions, with disagreement resolved by consensus. Data was extracted independently 179 by two researchers using a purposely developed data extraction tool in Covidence (CMC, PM), see S3 180 Appendix for a list of all data points extracted. Methodological quality assessment was assessed 181 independently by two reviewers using the Cochrane EPOC risk of bias tool (CMC, PM) (20).

182 Analysis

183 The Template for Intervention Description and Replication (TIDieR) checklist (21) was used as a 184 framework to narratively summarise interventions. For multi-faceted interventions this framework 185 was utilised to describe the interactive dashboard component alone. We categorised effectiveness 186 based on intervention type (for example if there was a truly interactive component to the dashboard 187 or whether the dashboard was part of a multi-faceted intervention), outcome of interest (e.g. high-188 risk prescribing or antibiotic prescribing rates) and study design. A meta-analysis using a random-189 effects model was performed where at least two studies were comparable in terms of participants, 190 study design and outcomes. Heterogeneity across studies was assessed using the I² statistic, with an 191 I² value greater than 50% considered indicative of substantial heterogeneity. Although 12 studies were

- identified, a funnel plot was not performed due to the heterogeneity in study design and outcomes.
- 193 Instead, a narrative assessment was conducted, acknowledging the potential limitations in detecting
- 194 publication bias.
- 195

196 **Results**

197 Search Results

A total of 12,918 records were identified from database searching and a further 197 from other sources. Following deduplication, 10,733 records were screened, with 119 full texts assessed for eligibility, and 12 studies, reported in 11 different papers, were included in the review, Figure 1. See S4 Appendix for a table of the excluded studies from full text review and their reason for exclusion.

- 202
- 203 <Insert Figure 1>
- 204 Figure 1 Study flow diagram

205 Characteristics of included studies

206 Of the 12 included studies, three were interrupted time series analyses (ITSA) (22-24), one was a 207 controlled before and after study (25) and eight were RCTs (26-32). Four of the RCTs were a cluster 208 design (27, 29, 31, 32). Two RCTs that targeted individual physician antibiotic prescribing were 209 individually randomised at the physician level (26, 30) and the final RCT was a stepped wedge design 210 where six clusters were sequentially allocated to the intervention every month (28). One paper 211 described randomly assigning practices to one of two parallel cRCTs (32). In each cRCT, the control 212 group in one trial served as the intervention group in the other, leading to a total of four distinct studies reported in the same paper. These studies were conducted simultaneously with the same 213 214 intervention but focused on different outcomes. However, only two of these four studies were 215 relevant for this systematic review, as the outcomes of the other two were not relevant. Therefore, 216 both of the relevant studies from this paper were included in this review (32). In seven of the included

217 papers, one ITSA and six RCTs, participants (either individual prescribers or practices) were unaware 218 they had been recruited (23, 26, 27, 29-32). In two additional studies it is unclear whether 219 practices/physicians were recruited and consented (22, 28) and in the final two studies practices from 220 a defined region were invited to participate (24, 25). The number of participants included in the 221 individual studies ranged from 12 to 1,401 practices and 43 to 3,426 physicians. None of the included 222 studies recruited individual patients. Five studies (reported in four papers) counted the number of 223 patients on whom the outcomes were assessed (i.e. included a denominator and numerator at the 224 participant level) (23, 25, 29, 32). Six studies focused on antibiotic prescribing and used aggregated 225 data, for example the rate of antibiotic prescriptions per 100 consultations or the proportion of all 226 antibiotics that were broad-spectrum (22, 24, 26-28, 30). The remaining six studies (reported in five 227 papers) focused on high-risk or potentially inappropriate prescribing (23, 25, 29, 31, 32). All of these 228 studies reported the number of patients potentially at risk and affected by potentially inappropriate 229 prescribing according to the criteria, except for one study that reported the mean number of patients 230 per practice with an inappropriate bronchodilator prescription, but did not provide the numerator and 231 denominator (31).

Lead author, year, country	Design	Physicians/practices targeted for intervention	Patients outcome assessed	Prescribing outcome
Aghlmandi (2023,	iRCT	3426 top abx	N/A	Antibiotic prescribing
Switzerland) (26)		prescribing physicians		rate
Curtis (2021, UK)	3-arm	1401 top abx	N/A	Board spectrum
(27)	cRCT	prescribing practices		antibiotic use
Davidson (2023,	ITSA	162 practices	N/A	Antibiotic prescribing
USA) (22)				rate
deLusigan (2021,	CBA	12 practices	807	Inappropriate aspirin
UK) (25)			8	Inappropriate metformin
Dutcher (2021,	SW-RCT	31 practices	N/A	Antibiotic prescribing
USA) (28)				rate
Guthrie (2016, UK)	3-arm	262 practices	170,659	Composite measure of
(29)	cRCT			high-risk prescribing

All rights reserved. No reuse allowed without permission.

Lead author, year, country	Design	Physicians/practices targeted for intervention	Patients outcome assessed	Prescribing outcome
Hemkins (2017,	iRCT	2900 top abx	N/A	Antibiotic prescribing
Switzerland) (30)		prescribing physicians		rate
MacBride-Stewart	cRCT	235 practices	N/A	Inappropriate SABA and
(2022, UK) (31)				LABA prescriptions
Peek (2020, UK)	ITSA	43 practices	54,044	Composite measure of
(23)				high-risk prescribing
Soucy (2024, Israel/	ITSA	43 physicians	N/A	Antibiotic prescribing
Canada) (24)				rate
Willis (2020, UK)	cRCT	80 practices	67,475	Inappropriate aspirin or
(32)*				NSAID prescribing
Willis (2020, UK)	cRCT	64 practices	99,829	Inappropriate
(32)*				anticoagulant in A. Fib

* This study recruited for two trials concurrently; 80 practices were randomised to a trial exploring the effect of
 feedback of high risk NSAID and antiplatelet prescribing and 64 to explore the effect of feedback on appropriate
 anticoagulant prescribing for atrial fibrillation.

Abbreviations: iRCT; individually randomised controlled trial, Abx; antibiotic, cRCT; cluster randomised controlled trial, ITSA; interrupted time series analysis, CBA; controlled before and after study, SW-RCT; stepped wedge randomised controlled trial, SABA; short acting beta agonist inhaler, LABA; long acting beta agonist inhaler,

- 240 NSAID; non-steroidal anti-inflammatory drug.
- 241

242 Characteristics of interventions

243 Although 12 studies, are included in this review, two studies were reported in the same paper and 244 used the same study processes and intervention type but focused on different outcomes. For the 245 purpose of describing the intervention, these two studies are considered as one. The characteristics of the interactive dashboards of the included studies are described based on the TIDieR checklist in 246 247 Table 2 (21). The tailoring and modifications components of this framework were generally not 248 applicable as these are often more relevant to implementation programmes, where interventions may 249 need to be adapted to fit specific contexts or populations (21). The interventions identified in this 250 systematic review were all designed for use within the context in which they were implemented. Only 251 one study reported a modification where antibiotic prescribing feedback was initially based on the 252 dispensing claim's date, but in the second year of the study this was modified to reflect the actual prescription date (30). Four of the 11 interventions included had a true interactive component where 253 254 the user could directly manipulate their data and had unlimited access to the dashboard within a

- defined period of time (22, 23, 25, 27). The remaining seven interventions all provided prescribers
- with longitudinal access to relatively real-time data. Six of the eleven studies included multi-faceted
- interventions, where the interactive dashboard was part of a broader programme (22, 23, 27-29, 32).
- 258 Two of these were three arm cRCTs where one of the arms received an additional behavioural change
- component (27, 29). Two dashboards also alerted prescribers to individual patients with high-risk
- 260 prescribing/ inadequate blood-test monitoring (23) or inappropriate bronchodilator prescriptions
- 261 (31).

Table 2 Characteristics of interventions

Study ID Intervention name	Multi-faceted?	Why?	What?	Who provided it?	How and where?	When and how much?	How well?
Interventions w	ith a true interacti	ve component					
Curtis 2021 (27)	Yes, arm 3 feedback included one page theory informed behavioural change component.	To increase engagement with prescribing data and change prescribing.	Link to specific metrics on publicly available prescribing dashboard with either plain or specific feedback.	Dashboard publicly available at openprescribing.net. Link and feedback provided by research team.	Link and feedback sent by post, email and fax.	May - July 2018, monthly for 3 months	Dashboard engagement measured using Google analytics.
Davidson 2023, CHOSEN (22)	Yes, web platform which included webinars on antimicrobial stewardship, how to use the dashboard and resources for patients.	To reduce inappropriate antibiotic prescribing	Web-based platform that provided interactive visualisations of abx prescribing rate that was updated on a monthly basis. Data could be explored by visit type, primary location and provider. Monthly and yearly trends were displayed with an overall rate and a target rate.	Research team	Web-based dashboard which could be accessed during study period.	Accessible at any time from February 2018	No mention of usage analytics
deLusignan 2021 (25)	No	To reduce inappropriate metformin and aspirin prescribing	Dashboard to allow GPs monitor their prescribing of metformin for patients with eGFr < 30 and >30>40 and aspirin for	Research team	Dashboard built directly into EHR	Metformin dashboard available from April- July2019. Aspirin	Not measured

Study ID Intervention name	Multi-faceted?	Why?	What?	Who provided it?	How and where?	When and how much?	How well?
			patients with T2DM who do not have CKD/CVD			dashboard available from July -Oct 2019	
Peek 2020, SMASH (23)	Yes, clinical pharmacists trained to deliver the intervention in partnership with general practice staff. Feedback included educational material about each of the included indicators.	To reduce hazardous prescribing and inadequate blood-test monitoring	Interactive dashboard that provided feedback on prevalence of each hazardous prescribing and inadequate blood- test monitoring indicator with comparisons to the CCG average. Data was displayed in both tabular and graph format. Individual patients at risk were also listed by NHS number.	NHS- phased roll out based on NICE guidance	Web-based interactive dashboard	Data updated on a daily basis and available to practices from April 2016.	Not measured
Interventions w	vithout a true inter	active component	·				
Aghlmandi 2023 (26)	No	To improve abx prescribing rates amongst higher rate prescribers.	Graphic abx prescribing report comparing prescribing rates to the previous 3 months and to peers.	Research team using insurance claims data	Email to the physician	Quarterly email from December 2017- September 2019	Not measured
Dutcher 2021 (28)	Yes, once-off educational session on appropriate prescribing for RTIs	To reduce antibiotic prescribing for RTIs	Graphic report displaying overall antibiotic prescribing rate and inappropriate RTI abx prescribing rates with	Research team	Automatically generated reports with data extracted from EHR -	Monthly feedback from October 2017 - October 2018	Not measured

Study ID Intervention name	Multi-faceted?	Why?	What?	Who provided it?	How and where?	When and how much?	How well?
			comparisons to the average and best performing practices.		emailed to practice		
Guthrie 2016, EFFIPPS (29)	Yes, all three arms were emailed educational material. Arm 3 feedback included a 1- page theory informed behavioural change component.	To improve the safety of primary care prescribing	Graphic report comparing the practice's high risk prescribing against the rate achieved by the 25th percentile of Scottish practices with the most optimal rates in the year before feedback started.	NHS Scotland Information Services Division	Email to practice	Five emails sent quarterly from June 2012 - June 2013	Not measured
Hemkens 2017 (30)	No	To reduce antibiotic prescribing	Graphs showing monthly trend in the physician's abx prescribing rate per 100 consultations and compared to the adjusted peer average.	Research team	Posted report with access code to the study website for more detailed feedback	8 postal feedbacks between October 2013 and July 2015	Not measured
MacBride- Stewart 2022 (31)	No	To reduce inappropriate prescriptions of bronchodilator inhalers.	Tables comparing inappropriate SABA or LABA prescriptions with the rest of the health board. List of individual patients identified as receiving inappropriate prescriptions.	Report developed by research team but also had signatures from three key lead clinicians in the health board.	Emailed to secure practice address and copied to the practice's prescribing support team pharmacist.	Three times: July 2015, February 2016 and August 2016.	69.2% practices discussed feedback with team. 80.4% reviewed ≥1 patient record. 77.6% flagged ≥1. patient record.

Study ID Intervention name	Multi-faceted?	Why?	What?	Who provided it?	How and where?	When and how much?	How well?
							62.6% consulted with ≥1 patient.
Soucy 2024, OPEN Stewardship (24)	No	To reduce antibiotic prescribing rate	Personalised prescribing reports displaying overall abx prescribing rate, rates for specific conditions and comparisons against the average and 25th percentile for other intervention participants	Research team	Report emailed directed to physicians	Quarterly for 9 months	Not measured
Willis 2020, ASPIRE (32)	Yes, practices were offered two training sessions by pharmacist, CDSS prompts for risky prescribing and tools to search for high-risk patients	To target barriers to change prescribing for four quality indicators.	Practice specific report displaying temporal trends for each of the trial indicators in number and graph form. Practices were also ranked and compared to others in the CCG.	Research team	Reports sent by post and email to the practice	Quarterly from May 2015-March 2016	Implementation will be assessed via process evaluation

Abbreviations: Abx; antibiotic, EHR; electronic health record, eGFR; estimated glomerular filtration rate, CKD; chronic kidney disease, CVD; cardiovascular disease, CCG; clinical commissioning group, NHS; National Health Service, NICE; National Institute for Clinical Excellence, RTI; respiratory tract infection, SABA; short-acting beta-agonist, LABA; long-acting beta agonist, CDSS; clinical decision support-system.

262 Risk of bias in included studies

263 Overall nine of the 11 included papers had a low risk of bias (22, 23, 26-32), Figure 2 (the two studies 264 reported within the one paper were assessed as one as they had the same methodological design and 265 study processes). See S5 Appendix for risk of bias graphs summarising the risk for each EPOC criterion. 266 One ITSA had a moderate risk of bias (24), where there were significant losses to follow up amongst 267 Canadian physicians that was inadequately addressed, in addition the COVID-19 pandemic was likely 268 to have influenced antibiotic prescribing during the intervention period. There was also insufficient 269 information on prevention of knowledge of allocated interventions and crude post-intervention 270 prescribing rates were not presented which limited transparency (24). The included controlled before 271 and after study had a high risk of bias, by virtue of its design (25). In addition there was a significant 272 improvement in inappropriate aspirin prescribing prior to intervention implementation, this was 273 clearly reported by the authors' but unexplained (25), given this finding the intervention effect was 274 not considered significant for the purpose of this review.

275

<Insert Figure 2>

276 Figure 2 Cochrane Effective Practice and Organisation of Care Risk of bias summary

277 Effectiveness of interventions

278 Overall, six of the 12 included studies, two ITSAs (22, 23) and four RCTs (28, 29, 31, 32) demonstrated 279 a significant effect on prescribing-related outcomes, Table 3. When exploring the intervention effect 280 by outcome measure, two of the six studies that targeted antibiotic prescribing had a significant effect 281 (22, 28). One was a prospective interrupted time series design where practices after the pre-282 intervention and wash-out periods received access to a web platform that provided educational 283 material and interactive dashboards (22). Data was updated on a monthly basis and displayed as 284 graphs illustrating monthly and yearly trends in the antibiotic prescribing rate that could be explored 285 by visit type, primary location and provider (22). The effect of the intervention was explored by 286 provider type (paediatric, internal medicine, family physicians and urgent care) with the family

287 physician rate reported here, Table 3. The largest effect size was seen for this group, although 288 significant results were seen in all groups (22). The other study that showed a significant effect on 289 antibiotic prescribing was an RCT that focused on inappropriate antibiotic prescribing for respiratory 290 tract infections (28), with the outcome measured at the visit level (i.e. the proportion of respiratory 291 tract infection visits that resulted in the prescription of an antibiotic). Participating practices received 292 an educational package and monthly reports by email which displayed the overall antibiotic 293 prescribing rate and the rates of inappropriate antibiotic prescribing for defined respiratory tract 294 infections, both of which were compared to the average and best performing practices (28). The 295 remaining four studies that targeted antibiotic prescribing failed to show an effect on antibiotic 296 prescribing rates (24, 26, 30) or broad-spectrum antibiotic prescribing (27).

297 Six studies (reported in five papers) explored the effect on inappropriate prescribing for other drugs 298 groups (see S6 Appendix for a list of the indicators included in these studies) and four of these 299 demonstrated a significant effect (23, 29, 31, 32). The remaining study exploring the effect on PIP was 300 a controlled before and after study that had a high risk of bias (25). Although the authors reported a 301 significant effect on inappropriate aspirin prescribing there was an unexplained significant 302 improvement in this indicator during phase one of the study prior to the implementation of the aspirin 303 dashboard (25). In addition no rates or inferential statistics for the effect of the dashboard on 304 inappropriate metformin prescribing were reported as there were only 8 patients prescribed this 305 medicine at follow up (25). The four studies that demonstrated a significant effect on PIP included one 306 ITSA and three RCTs. The ITSA explored the effect of the routine roll-out of the SMASH intervention 307 that provided feedback on the prevalence of each hazardous prescribing and inadequate blood-test 308 monitoring indicator with comparisons to the local area (clinical commissioning group) average (23). 309 There was a significant effect on high-risk prescribing (ARR -0.96%, 95% CI -1.12% to -0.79%) but not 310 on inadequate blood-test monitoring (23), however there was a significant effect seen on the latter 311 outcome at 24 weeks follow-up. In addition the largest reductions in high-risk prescribing were seen

312	in practices with higher baseline rates and by 12 months follow-up there was significantly reduced
313	inter-practice variation in the rates of potentially hazardous prescribing and inadequate blood test
314	monitoring (23). The remaining three studies demonstrating a significant effect on PIP were RCTs
315	where feedback with comparative rates of each of the included indicators were emailed to the practice
316	every quarter (29, 31, 32).
317	With respect to the intervention components five of the six studies that had multi-faceted
318	interventions showed a significant effect (22, 23, 28, 29, 32), compared to one (31) of the five studies
319	that just had the interactive dashboard component. Two cRCTs that identified individual patients
320	within the dashboard (hazardous prescribing/inadequate blood test monitoring or inappropriate
321	bronchodilator prescribing) both had a significant effect (31, 32).

322

323 Table 3 Results of included studies

Lead author, year, country	Outcome description	Effect size						
Randomised controlled trials								
Aghlmandi (2023,	Abx prescribing rate per 100 consultations	ARR –0.1% (95% CI, –1.2%						
Switzerland) (26)	during the second year of the intervention	to 51.0%)						
Curtis (2021, UK) (27)		Coefficient -0.31%, (95%						
	Percentage of abx that are broad spectrum	CI –0.7% to 0.1%)						
	Percentage of abx that are broad spectrum	Coefficient 0.41%, (95% Cl						
		0.007% to 0.800%) [¥]						
Dutcher (2021, USA)	Proportion of RTI visits with abx	OR 0.47 (95% Cl 0.45 to						
(28)		0.48)						
Guthrie (2016, UK)	Proportion of patients included in one or	OR 0.88 (95% Cl 0.80 to						
(29)	more of the 6 criteria who received a high-	0.96)						
	risk prescription	OR 0.86 (95% Cl 0.78 to						
		0.95) [₱]						
Hemkins (2017,	Antibiotic prescription rate measured as	ARR 0.81% (95% CI -2.56%						
Switzerland) (30)	DDD per 100 consultations	to 4.30%)						
MacBride-Stewart	Mean number of patients with an	Mean difference -3.7 (95%						
(2022, UK) (31)	inappropriate SABA or LABA prescription	Cl -5.3 to -2.0)						
Willis (2020, UK) (32)*	Proportion of patients with at least 1 high	OR 0.815 (97.5% Cl 0.67 to						
	risk NSAID or anti-platelet indicator	0.99)~						
Willis (2020, UK) (32)*	Proportion of patients with AF prescribed	OR 0.902 (97.5% Cl 0.75 to						
	inappropriate anticoagulation therapy	1.09)						
Controlled before and after study								

Lead author, year, country	Outcome description	Effect size			
deLusigan (2021, UK) (25)	Proportion of patients incorrectly prescribed (a) metformin and (b) aspirin	(a) [§] (b) OR 0.44 (95% Cl 0.27 to 0.72) ^μ			
	Interrupted time series analyses				
Davidson (2023, USA) (22)	Percentage of total visits with abx prescription [¶]	Pre–post relative difference in rates -20.4 % Level change β Coefficient -7.95 (95% CI –11.05 to -4.85)			
Peek (2020, UK) (23)	Prevalence of exposure to (a) any potentially hazardous prescribing (10 indicators) and (b) any inadequate blood- test monitoring (2 indicators) among patients with risk factors for such prescribing and monitoring 12 months after intervention start	(a) ARR -0.96% (95% CI - 1.12% to -0.79%) (b) ARR −2.85% (95% CI −5.68% to 0.71%)			
Soucy (2024, Israel/	Proportion of total visits with abx	OR 1.01; 95% CI 0.94 to			
Canada) (24)	prescription d behavioural change component, arm 2 was feedback	1.07)			
	isk reduction, OR; odds ratio, Abx; antibiotic, RTI; respirat ta agonist inhaler, LABA; long-acting beta agonist inha ug				
Four of the eight include	d RCTs measured the effect of the interventic	n on potentially inappropriate			
prescribing and presente	d results as proportions and odds ratios with	95% confidence intervals (two			
of these trials were rep	orted within the one paper) (28, 29, 32). H	owever, one of these studies			
measured the proportior	n of inappropriate prescriptions at the visit lev	el (28), the others were at the			
patient level (29, 32). Thi	us the three RCTs looking at the effect on app	ropriate prescribing measured			
at the patient level were included in the meta-analysis, where the overall effect size was OR 0.87 (95%					
CI 0.81 to 0.93), with a low heterogeneity ($I^2 = 0.0\%$), see Figure 2. This lack of heterogeneity can be					
attributed to the similar intervention types across the included trials, as all three studies involved					
quarterly feedback reports giving temporal trends in prescribing across a series of high-risk metrics					
and ranked practices within the local area for comparison. 20					

346 <Insert Figure 3>

Figure 3 Forest plot of randomised controlled trials exploring the intervention effect on patient level prescribing
 appropriateness

- 349 Abbreviations: CI; confidence interval, RP; risky prescribing, AF; atrial fibrillation
- 350

351 Discussion

352 Summary of results

353 This systematic review aimed to explore the characteristics of interactive dashboard interventions 354 designed to support safe prescribing and explore their effect on prescribing-related outcome 355 measures. Given the nature of the intervention, where data is often fed back on a widespread basis 356 and implemented as a policy, quasi-experimental designs, were included. Six of the 12 included studies 357 demonstrated a significant effect and all of these had an overall low risk of bias (22, 23, 28, 29, 31, 358 32). Notably, only two of the six studies that explored the effect of these interventions on antibiotic 359 prescribing showed a significant effect (28). It may be that recent campaigns to improve antimicrobial 360 stewardship have already resulted in improvements, leaving less room for further advancements. Four 361 of the five studies looking at potentially inappropriate prescribing showed a significant effect (23, 29, 362 31, 32). Potentially inappropriate or high-risk prescribing is more common in complex patients with 363 multimorbidity and polypharmacy (2) and lack of prescriber awareness has been identified as a barrier 364 to addressing this (33). Thus, the difference in effect seen by outcome measure may be because PIP is 365 often related to clinician oversight, whereas antibiotic prescribing reflects a more direct clinician decision and thus may be less amenable to change. This hypothesis is supported by the fact that both 366 interventions that alerted prescribers to specific instances of PIP had a significant effect (23, 31). 367 368 Similar to results presented in other systematic reviews exploring the effectiveness of interventions 369 in addressing inappropriate polypharmacy (34), multi-faceted interventions were more often effective 370 with five of the six multi-faceted interventions demonstrating a significant effect (22, 23, 28, 29, 32). 371 In summary, interventions targeting potentially inappropriate prescribing, that included multifaceted 372 elements seemed to have a beneficial effect on outcomes.

373 Audit and feedback is known to lead to small improvements in professional behaviour, as evidenced 374 by a systematic review of 140 studies, including a meta-analysis of 108 comparisons from 70 studies, 375 which found a median absolute increase of 4.3% in healthcare professionals' compliance with desired 376 practices (9). Increased frequency of feedback, coupled with explicit, measurable targets and specific 377 action plans, were associated with greater effectiveness (9). The interventions included in this review 378 all included ongoing feedback of relatively contemporaneous data, with comparisons to specific set 379 targets or comparative benchmarking. The three studies included in our smaller meta-analysis 380 estimated a 13% reduction in the odds of high-risk prescribing when the intervention was applied, 381 consistent with the findings above. Similar to pervious findings, interventions that identified particular 382 instances of high-risk prescribing and multi-faceted interventions had positive findings more often 383 compared to studies that did not incorporate these features (9). With recent advancements in data 384 infrastructure and machine learning techniques, the potential to scale these interventions has 385 increased. Even a modest effect, when implemented at scale, could have significant implications for 386 health systems and individual patients.

387 Strengths and limitations

This systematic review included a broad and detailed search strategy including citation chasing and grey literature searches of clinical trial registries to reduce the risk of publication bias. Including quasiexperimental designs meant we captured two large ITSAs that explored the implementation of novel interactive dashboards. Given the heterogeneous nature of the outcome measures included (different prescribing criteria, measured at different levels (e.g. practice and visit level as well as patient level) it was only possible to perform a meta-analysis for three studies and it was not possible to conduct a funnel plot to formally assess publication bias.

395

396 Implications for research, policy and practice

397 Developing true interactive dashboards directly embedded into practices systems that allow clinicians 398 to identify specific instances of high risk prescribing and compare their prescribing quality with peers, 399 has the potential for significantly supporting safe and effective prescribing. However, this approach 400 will involve necessary collaboration with the software vendors, who are often private enterprises and 401 thus driven by cost containment. In addition, the cost of such developments will be mostly incurred 402 by practices who purchase these software systems. Encouraging competition between software 403 providers, incentivising software providers to develop these inbuilt systems to enhance quality and 404 safety and, as such systems becomes the norm, updating regulatory standards for practice software 405 systems may increase implementation. A second complication of identifying high-risk prescribing is 406 the need for patient-level factors such as co-prescriptions, age and co-morbidities, meaning this 407 analysis needs to occur within the practices' own databases with only aggregate data exported for 408 benchmarking purposes. In addition, there may be legal and data regulation implications about 409 sharing this aggregate data, although in the UK aggregate practice-level analysis of publicly available 410 prescribing data is available for the public to view at openprescibing.net. This approach is low cost, 411 but feedback using this anonymous publicly available data is less granular, and as was demonstrated 412 in this review, feedback of practice level prescribing rates may be less effective at changing prescriber 413 behaviour.

This review identified several gaps in the existing literature. Only 12 studies met the inclusion criteria, with just four employing true interactive dashboards. The limited number of studies suggests a need for further research exploring the effectiveness of interactive dashboards designed to optimise prescribing. A key challenge in conducting the meta-analysis was the heterogeneity of outcome measures, which were reported at various levels, including the prescription, patient, prescriber, and practice levels. The development of a core outcome set for prescribing-related measures that can be consistently applied across studies utilising routine prescribing or dispensing datasets may be one way

of addressing this and would facilitate more meaningful comparisons and benefit future metaanalyses. Finally, routine evaluations of policies that utilise this data to optimise prescribing are essential. Systematic and standardised evaluations would provide valuable insights into the effectiveness of policy interventions aimed at optimising prescribing, thereby enhancing clinical outcomes and health system efficiency.

426

427 **Conclusion**

- 428 Interactive dashboards have the potential to support safe and effective prescribing in primary care.
- 429 Multi-faceted interventions that target high-risk prescribing are more likely to be effective. To support
- 430 their implementation, it is essential to establish the necessary data infrastructure within primary care
- 431 systems. With advancements in data infrastructure and analysis, these interventions could have a
- 432 significant impact if implemented at scale.

433 Supporting Information

- 434 S1 Appendix: PRISMA Checklist
- 435 S2 Appendix: Electronic search reports
- 436 S3 Appendix: List of all data points extracted from included studies
- 437 S4 Appendix: List of all studies with reasons for exclusion from full text review
- 438 S5 Appendix: Risk of bias graphs
- 439 S6 Appendix: List of all endpoints for included studies

440 Acknowledgments:

- 441 Killian Walsh; Information Specialist, RCSI library assisted with search strategy. Mobeena Naz; Medical
- 442 Student, RCSI assisted with title and abstract screening.
- 443
- 444

All rights reserved. No reuse allowed without permission.

445

References

446

Fortin M, Lapointe L, Hudon C, Vanasse A, Ntetu AL, Maltais D. Multimorbidity and quality of
 life in primary care: a systematic review. Health and Quality of Life Outcomes. 2004;2:51.

Pérez T, Moriarty F, Wallace E, McDowell R, Redmond P, Fahey T. Prevalence of potentially
 inappropriate prescribing in older people in primary care and its association with hospital admission:
 longitudinal study. BMJ. 2018;363:k4524.

452 3. Wallace E, Salisbury C, Guthrie B, Lewis C, Fahey T, Smith SM. Managing patients with 453 multimorbidity in primary care. BMJ. 2015;350:h176.

454 4. Jung Yin Tsang MS, Thomas Blakeman, Rupert Payne, Darren M Aschcroft. Protocol for the 455 development and validation of a Polypharmacy Assessment Score for potentially problematic 456 polypharmacy PREPRINT (Version 1) available at Research Square 2023.

457 5. Chang CB, Chan DC. Comparison of published explicit criteria for potentially inappropriate
 458 medications in older adults. Drugs Aging. 2010;27(12):947-57.

6. Radomski TR, Decker A, Khodyakov D, Thorpe CT, Hanlon JT, Roberts MS, et al. Development
of a Metric to Detect and Decrease Low-Value Prescribing in Older Adults. JAMA network open.
2022;5(2):e2148599-e.

462 7. Dimitrow MS, Airaksinen MS, Kivela SL, Lyles A, Leikola SN. Comparison of prescribing criteria
463 to evaluate the appropriateness of drug treatment in individuals aged 65 and older: a systematic
464 review. J Am Geriatr Soc. 2011;59(8):1521-30.

465 8. Curtis HJ, Goldacre B. OpenPrescribing: normalised data and software tool to research trends
466 in English NHS primary care prescribing 1998–2016. 2018;8(2):e019921.

467 9. Ivers N, Jamtvedt G, Flottorp S, Young JM, Odgaard-Jensen J, French SD, et al. Audit and
468 feedback: effects on professional practice and healthcare outcomes. Cochrane Database Syst Rev.
469 2012(6):Cd000259.

470 10. Kwan JL, Lo L, Ferguson J, Goldberg H, Diaz-Martinez JP, Tomlinson G, et al. Computerised
471 clinical decision support systems and absolute improvements in care: meta-analysis of controlled
472 clinical trials. 2020;370:m3216.

473 11. Williams R, Keers R, Gude WT, Jeffries M, Davies C, Brown B, et al. SMASH! The Salford
474 medication safety dashboard. 2018;25(3):183-93.

475 12. Cole JA, Gonçalves-Bradley DC, Alqahtani M, Barry HE, Cadogan C, Rankin A, et al.
476 Interventions to improve the appropriate use of polypharmacy for older people. Cochrane Database
477 Syst Rev. 2023(10).

478 13. Mekonnen AB, Redley B, de Courten B, Manias E. Potentially inappropriate prescribing and its
479 associations with health-related and system-related outcomes in hospitalised older adults: A
480 systematic review and meta-analysis. Br J Clin Pharmacol. 2021;87(11):4150-72.

481 14. Daoust R, Paquet J, Marquis M, Chauny J-M, Williamson D, Huard V, et al. Evaluation of
482 Interventions to Reduce Opioid Prescribing for Patients Discharged From the Emergency Department:
483 A Systematic Review and Meta-analysis. JAMA network open. 2022;5(1):e2143425-e.

Mattsson M, Boland F, Kirke C, Flood M, Wallace E, Walsh ME, et al. The impact of lidocaine
plaster prescribing reduction strategies: A comparison of two national health services in Europe. Br J
Clin Pharmacol. 2023;89(8):2349-58.

Moynagh P, Mannion, Á, Wei, A, Clyne, B, Moriarty, F, McCarthy, C. Effectiveness of interactive
dashboards to optimise prescribing in primary care: a protocol for a systematic review [version 1; peer
review: awaiting peer review]. HRB open research. 2024;7(44).

490 17. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane Handbook for 491 Systematic Reviews of Interventions version 6.4 (updated August 2023): Cochrane; 2023. Available

492 from: www.training.cochrane.org/handbook.

493 18. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA
494 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021:n71.

Haddaway NR, Grainger MJ, Gray CT. Citationchaser: A tool for transparent and efficient
forward and backward citation chasing in systematic searching. Research synthesis methods.
2022;13(4):533-45.

49820.Cochrane Effective Practice and Organisation of Care (EPOC). What study designs can be499considered for inclusion in an EPOC review and what should they be called? 2017 13/03/2024.500Availablefrom:

501 <u>https://epoc.cochrane.org/sites/epoc.cochrane.org/files/uploads/EPOC%20Study%20Designs%20Ab</u>
 502 <u>out.pdf</u>.

503 21. Hoffmann TC, Glasziou PP, Boutron I, Milne R, Perera R, Moher D, et al. Better reporting of
504 interventions: template for intervention description and replication (TIDieR) checklist and guide.
505 2014;348:g1687.

Davidson LE, Gentry EM, Priem JS, Kowalkowski M, Spencer MD. A multimodal intervention to
 decrease inappropriate outpatient antibiotic prescribing for upper respiratory tract infections in a
 large integrated healthcare system. Infect Control Hosp Epidemiol. 2023;44(3):392-9.

Peek N, Gude WT, Keers RN, Williams R, Kontopantelis E, Jeffries M, et al. Evaluation of a
pharmacist-led actionable audit and feedback intervention for improving medication safety in UK
primary care: An interrupted time series analysis. PLoS Med. 2020;17(10):1-17.

Soucy Jean-Paul R, Low M, Acharya Kamal R, Ellen M, Hulth A, Löfmark S, et al. Evaluation of
an automated feedback intervention to improve antibiotic prescribing among primary care physicians
(OPEN Stewardship): a multinational controlled interrupted time-series study. Microbiology spectrum.
2024;12(4):e00017-24.

516 25. de Lusignan S, Hinton W, Seidu S, Mathew M, Feher MD, Munro N, et al. Dashboards to reduce
517 inappropriate prescribing of metformin and aspirin: A quality assurance programme in a primary care
518 sentinel network. Prim Care Diabetes. 2021;15(6):1075-9.

Aghlmandi S, Halbeisen FS, Saccilotto R, Godet P, Signorell A, Sigrist S, et al. Effect of Antibiotic
Prescription Audit and Feedback on Antibiotic Prescribing in Primary Care: A Randomized Clinical Trial.
JAMA internal medicine. 2023;183(3):213-20.

522 27. Curtis HJ, Bacon S, Croker R, Walker AJ, Perera R, Hallsworth M, et al. Evaluating the impact
523 of a very low-cost intervention to increase practices' engagement with data and change prescribing
524 behaviour: a randomized trial in English primary care. Fam Pract. 2021;38(4):373-80.

525 28. Dutcher L, Degnan KO, Adu-Gyamfi AB, Lautenbach E, Cressman L, David MZ, et al. Improving
526 Outpatient Antibiotic Prescribing for Respiratory Tract Infections in Primary Care; a Stepped-Wedge
527 Cluster Randomized Trial. Clinical infectious diseases : an official publication of the Infectious Diseases
528 Society of America. 2021;74(6):947-56.

529 29. Guthrie B, Kavanagh K, Robertson C, Barnett K, Treweek S, Petrie D, et al. Data feedback and
530 behavioural change intervention to improve primary care prescribing safety (EFIPPS): multicentre,
531 three arm, cluster randomised controlled trial. BMJ (Clinical research ed). 2016;354:i4079.

30. Hemkens LG, Saccilotto R, Leon Reyes S, Glinz D, Zumbrunn T, Grolimund O, et al. Personalized
Prescription Feedback Using Routinely Collected Data to Reduce Antibiotic Use in Primary Care: A
Randomized Clinical Trial. JAMA internal medicine. 2017;177(2):176-83.


535 31. MacBride-Stewart S, Marwick C, Ryan M, Guthrie B. Feedback of actionable individual patient
536 prescription data to improve asthma prescribing: pragmatic cluster randomised trial in 233 UK general
537 practices. Br J Gen Pract. 2022;72(722):e627-33.

538 32. Willis TA, Collinson M, Glidewell L, Farrin AJ, Holland M, Meads D, et al. An adaptable 539 implementation package targeting evidence-based indicators in primary care: A pragmatic cluster-540 randomised evaluation. PLoS Med. 2020;17(2):1-20.


541 33. Anderson K, Stowasser D, Freeman C, Scott I. Prescriber barriers and enablers to minimising potentially inappropriate medications in adults: a systematic review and thematic synthesis. BMJ 542 open. 2014;4(12). 543

34. Clyne B, Fitzgerald C, Quinlan A, Hardy C, Galvin R, Fahey T, et al. Interventions to Address 544

545 Potentially Inappropriate Prescribing in Community-Dwelling Older Adults: A Systematic Review of 546 Randomized Controlled Trials. J Am Geriatr Soc. 2016;64(6):1210-22.



The Effectiveness of Interactive Dashboards to Optimise Prescribing in Primary Care: A Systematic Review





NO IS: Weights are from random effects model